Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CTLA4 antibody Fc fusion protein KN044

A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CTLA4 antibody fusion protein KN044
Code name:KN 044
KN-044
KN044
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search